27th Aug 2026 17:00
(Alliance News) - Shield Therapeutics PLC shares spiked on Thursday afternoon after the pharmaceutical company announced it will assume full commercial responsibility for its ferric maltol supplement in the US.
Shares in Gateshead, England-based Shield were up 10% at 5.45 pence in London.
The company said it had agreed with Viatris Inc that Shield would take sole responsibility for the commercialisation of its iron replacement therapy Accrufer in the US as of September 30.
The two companies had been collaborating to grow Accrufer in the US market since 2022. Shield said the deal does not involve any upfront payments to Viatris but that it will pay Viatris a royalty on net sales for five years.
Shield said the deal gives the company direct control of its largest market. Shield Chief Executive Officer Anders Lundstrom said: "By assuming full commercial control of our most important market, we significantly enhance the economics of the business, strengthen our ability to execute our growth strategy and create a scalable commercial platform for the future."
By Camilla Borri, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Shield Thera